Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
Sebhat Erqou, Emerging Risk Factors Collaboration, John Danesh · Meta-analysis
BlueRipple Assessment
This is the large-scale epidemiology that anchored lipoprotein(a) as a genuine cardiovascular risk factor, drawing together individual data from over 126,000 people across many prospective studies.
The analysis established several durable facts. Lp(a) was only weakly correlated with the usual risk factors — meaning it carries independent information — and it was remarkably stable within individuals over years, supporting one-time measurement. Higher Lp(a) was continuously and independently associated with coronary heart disease and ischemic stroke (about a 13 percent higher risk per standard-deviation increase, after adjustment), with the association specific to vascular outcomes: there was no link to cancer or non-vascular death.
The associations were modest in magnitude but consistent and clean, providing the epidemiological backbone that, together with the genetic studies, made the case for taking Lp(a) seriously.
We rate the evidence strong. An individual-participant meta-analysis of this scale and care is high-grade epidemiology, and it remains a foundational citation for Lp(a)‘s independent, vascular-specific risk.
The original source
Emerging Risk Factors Collaboration; Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009 Jul 22;302(4):412-23. doi: 10.1001/jama.2009.1063.